Multimodal Prostate Cancer Evaluation

The analysis will be conducted according to the guidelines [4 (link)]. Specifically, specimens are labeled by location and, if applicable, whether they were obtained by SB, PET-TB, or MR-TB. Furthermore, the number of positive cores and the highest Gleason score per prostate lobe, per biopsy method, and per suspicious area (MRI and/or PSMA-PET/CT) are determined. Moreover, the loss of the tumor suppressor gene phosphatase and tensin homolog (PTEN) and PSMA expression will be determined in tumor-bearing biopsy specimens by immunohistochemistry. PSMA expression will be rated by an institutional-established valid semi-quantitative scale ranging from 0 to 3: “none,” “low,” “intermediate,” or “high,” respectively.